CLAIMS

- 1. A composition comprising T_3 , serum albumin and water wherein the stability of T_3 is increased.
- 2. The composition according to claim 1, wherein the T_3 has a half-life of at least five days at a temperature range of about -30° C to 70° C.
- 3. The composition according to claim 1, wherein further comprising a pharmaceutically acceptable excipient.
- 4. The composition according to claim 3, suitable for use in intravenous administration.
- 5. The composition according to claim 3, suitable for use in direct cardiac administration.
- 6. The composition according to claim 3, suitable for use in parenteral administration.
 - 7. The composition according to claim 3, suitable for use in mucosal administration.
- 8. The composition according to claim 7, wherein the mucosal administration is selected from the group consisting of intranasal, by-inhalation and buccal.
- 9. The composition according to claim 8, wherein the T₃ has a half-life of at least two weeks.
- 10. The composition according to claim 1, wherein the T₃ has a half-life of at least one month.
- 11. The composition according to claim 1, wherein the T_3 has a half-life of at least three months.
- 12. The composition according to claim 1, wherein the T_3 has a half-life of at least six months.
- 13. The composition according to claim 1, wherein the T_3 has a half-life of at least twelve months.
- 14. The composition according to claim 1, wherein the ratio of T_3 and the serum albumin is between about 0.001 and 0.1.
- 15. The composition according to claim 1, wherein the ratio of T_3 and the serum albumin is between 0.002 and 0.05.

- 16. The composition according to claim 3, wherein the serum albumin is human serum albumin.
- 17. The composition according to claim 3, wherein the serum albumin is bovine serum albumin.
- 18. The composition according to claim 1, wherein the T₃ has a concentration of between 0.02 mg/ml and 0.8 mg/ml.
- 19. The composition according to claim 1, wherein the T₃ has a concentration of between 0.01 mg/ml and 1.0 mg/ml.
- 20. The composition according to claim 1, wherein the T₃ has a concentration of between 0.1 mg/ml and 0.5 mg/ml.
- 21. The composition according to claim 1, wherein the T₃ has a concentration of about 0.1 mg/ml.
 - 22. The composition according to claim 1, wherein the pH range is about 2.5 to 11.5.
 - 23. The composition according to claim 1, wherein the pH range is about 4.0 to 10.
 - 24. The composition according to claim 1, wherein the pH range is about 6.0 to 8.0.
 - 25. The composition according to claim 1, wherein the pH range is about 6.5 to 7.5.
- 26. A method of treating of a patient with cardiac arrest, or with cardiac electrical standstill, to restore effective cardiac function, comprising administering to the patient a therapeutically effective amount of the composition according to claim 1.
- 27. The method according to claim 26, wherein the cardiac arrest is caused by electromechanical dissociation.
- 28. The method according to claim 26, wherein the cardiac electrical standstill is caused by a disease.
- 29. The method according to claim 26, wherein the composition is administered by direct injection to a heart cavity of the patient, or direct parenteral injection into a central venous line of the patient.
- 30. The method according to claim 26, wherein the composition is administered by parenteral injection or parenteral intravenous injection.
- 31. The method according to claim 26, wherein the composition is administered directly to the pulmonary system of the patient.

- 32. The method according to claim 26, wherein the composition is administered directly to the pulmonary system by direct endotracheal injection.
- 33. The method according to claim 26, wherein the composition is administered directly to the pulmonary system by infusion through a respiratory airway of the patient.
- 34. The method according to claim 26, wherein the composition is administered in at least one rapid bolus injection.
- 35. The method according to claim 26, wherein the composition is administered at between 0.1 and 20 μ g T₃ per kg of body weight.
- 36. The method according to claim 26, wherein the composition is administered at between 0.2 and 10 μ g T₃ per kg of body weight.
- 37. The method according to claim 26, wherein the composition is administered at between 0.3 and 5 μ g T₃ per kg of body weight.
- 38. The method according to claim 26, wherein the composition is administered at $100 \mu g T_3$ per kg of body weight.
- 39. The method according to claim 26, wherein the composition is administered via intravenous drip.
- 40. The method according to claim 26, wherein the composition is administered via mucosal delivery.